File Download
 
 
Supplementary

Conference Paper: Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
  • Basic View
  • Metadata View
  • XML View
TitleEfficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
 
AuthorsWong, D
Lai, CL
Seto, WK
Fung, J
Huang, FY
Hung, IFN
Yuen, RMF
 
KeywordsMedical sciences
Gastroenterology
 
Issue Date2011
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationThe 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754 [How to Cite?]
 
AbstractBACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.
 
DescriptionThis journal suppl. is Abstract Book of The International Liver Congress™ 2011
Posters
 
ISSN0168-8278
2013 Impact Factor: 10.401
 
DC FieldValue
dc.contributor.authorWong, D
 
dc.contributor.authorLai, CL
 
dc.contributor.authorSeto, WK
 
dc.contributor.authorFung, J
 
dc.contributor.authorHuang, FY
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorYuen, RMF
 
dc.date.accessioned2011-07-27T01:59:41Z
 
dc.date.available2011-07-27T01:59:41Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.
 
dc.descriptionThis journal suppl. is Abstract Book of The International Liver Congress™ 2011
 
dc.descriptionPosters
 
dc.description.otherThe 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754
 
dc.identifier.citationThe 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754 [How to Cite?]
 
dc.identifier.epageS303
 
dc.identifier.hkuros188152
 
dc.identifier.hkuros190367
 
dc.identifier.issn0168-8278
2013 Impact Factor: 10.401
 
dc.identifier.issuesuppl. 1
 
dc.identifier.spageS303
 
dc.identifier.urihttp://hdl.handle.net/10722/135917
 
dc.identifier.volume54
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.subjectMedical sciences
 
dc.subjectGastroenterology
 
dc.titleEfficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, D</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Seto, WK</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Huang, FY</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Yuen, RMF</contributor.author>
<date.accessioned>2011-07-27T01:59:41Z</date.accessioned>
<date.available>2011-07-27T01:59:41Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135917</identifier.uri>
<description>This journal suppl. is Abstract Book of The International Liver Congress&#8482; 2011</description>
<description>Posters</description>
<description.abstract>BACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<subject>Medical sciences</subject>
<subject>Gastroenterology</subject>
<title>Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction</title>
<type>Conference_Paper</type>
<identifier.hkuros>188152</identifier.hkuros>
<identifier.hkuros>190367</identifier.hkuros>
<identifier.volume>54</identifier.volume>
<identifier.issue>suppl. 1</identifier.issue>
<identifier.spage>S303</identifier.spage>
<identifier.epage>S303</identifier.epage>
<publisher.place>Netherlands</publisher.place>
<description.other>The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754</description.other>
</item>